The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.
作者信息
Winthrop Kevin L, Ku Jennifer H, Marras Theodore K, Griffith David E, Daley Charles L, Olivier Kenneth N, Aksamit Timothy R, Varley Cara D, Mackey Katherine, Prevots D Rebecca
机构信息
Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA
Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.
出版信息
Eur Respir J. 2015 Apr;45(4):1177-9. doi: 10.1183/09031936.00169114. Epub 2015 Jan 22.
Abstract
摘要
相似文献
1
The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.利奈唑胺治疗非结核分枝杆菌病的耐受性
Eur Respir J. 2015 Apr;45(4):1177-9. doi: 10.1183/09031936.00169114. Epub 2015 Jan 22.
2
Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity.在利奈唑胺引起毒性反应后，在肺部非结核分枝杆菌感染中延长使用特地唑胺。
J Antimicrob Chemother. 2017 Feb;72(2):625-628. doi: 10.1093/jac/dkw484. Epub 2016 Dec 20.
3
Nontuberculous Mycobacterial Infections in Children.儿童非结核分枝杆菌感染
Pediatr Rev. 2019 Apr;40(4):179-190. doi: 10.1542/pir.2018-0131.
4
Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.氯法齐明治疗原发性和复发性非结核分枝杆菌感染的安全性和有效性。
Chest. 2017 Oct;152(4):800-809. doi: 10.1016/j.chest.2017.04.175. Epub 2017 May 5.
5
Mycobacterium triplex pulmonary disease with acquired macrolide resistance in immunocompetent patients.免疫功能正常患者的三重分枝杆菌肺病伴获得性大环内酯类耐药
Clin Microbiol Infect. 2018 Jun;24(6):671-672. doi: 10.1016/j.cmi.2017.12.018. Epub 2018 Jan 5.
6
Cutaneous Tuberculosis and Nontuberculous Mycobacterial Infections at a National Specialized Hospital in China.中国一家国家级专科医院的皮肤结核和非结核分枝杆菌感染。
Acta Derm Venereol. 2019 Oct 1;99(11):997-1003. doi: 10.2340/00015555-3283.
7
Nontuberculous mycobacterial disease in childhood - update on diagnostic approaches and treatment.儿童非结核分枝杆菌病——诊断方法和治疗的最新进展。
J Infect. 2017 Jun;74 Suppl 1:S136-S142. doi: 10.1016/S0163-4453(17)30204-9.
8
New insights in the treatment of nontuberculous mycobacterial pulmonary disease.非结核分枝杆菌肺病治疗的新见解
Future Microbiol. 2017 Oct;12:1109-1112. doi: 10.2217/fmb-2017-0144. Epub 2017 Sep 20.
9
A case report and literature review of nontuberculous mycobacterial disease caused by Mycolicibacterkumamotonensis.一株熊本分枝杆菌引起的非结核分枝杆菌病病例报告及文献综述
Indian J Med Microbiol. 2024 Nov-Dec;52:100731. doi: 10.1016/j.ijmmb.2024.100731. Epub 2024 Sep 12.
10
Linezolid-associated optic neuropathy in a pediatric patient with Mycobacterium nonchromogenicum: A case report.一名患有非产色分枝杆菌的儿科患者出现与利奈唑胺相关的视神经病变：病例报告。
Medicine (Baltimore). 2017 Dec;96(50):e9200. doi: 10.1097/MD.0000000000009200.
引用本文的文献
1
Recent advances in immunopathogenesis and clinical practice: mastering the challenge-managing of non-tuberculous mycobacteria.免疫发病机制与临床实践的最新进展：应对非结核分枝杆菌感染的挑战与管理
Front Immunol. 2025 Mar 19;16:1554544. doi: 10.3389/fimmu.2025.1554544. eCollection 2025.
2
Treatment outcomes in NTM-PD in a high TB burden context.高结核病负担背景下非结核分枝杆菌肺病的治疗结果
IJTLD Open. 2024 Dec 1;1(12):547-555. doi: 10.5588/ijtldopen.24.0413. eCollection 2024 Dec.
3
effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical isolates.新型口服β-内酰胺酶抑制剂头孢洛布坦与口服β-内酰胺类药物联合对临床分离株的作用。
Microbiol Spectr. 2024 Jul 2;12(7):e0008424. doi: 10.1128/spectrum.00084-24. Epub 2024 Jun 6.
4
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.治疗非结核分枝杆菌感染的药物：来自意大利传染病和热带医学学会分枝杆菌研究组的叙述性综述。
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
5
Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease.利奈唑胺方案治疗脓肿分枝杆菌肺病的有效性和安全性。
Ann Clin Microbiol Antimicrob. 2023 Dec 6;22(1):106. doi: 10.1186/s12941-023-00655-2.
6
Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.唑烷酮类药物对鸟分枝杆菌复合体感染的细胞内和体内活性。
Sci Rep. 2023 Nov 23;13(1):20631. doi: 10.1038/s41598-023-48001-y.
7
Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus.奥马环素与其他抗菌药物联合对脓肿分枝杆菌的协同作用。
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0157922. doi: 10.1128/aac.01579-22. Epub 2023 May 8.
8
Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review.非结核分枝杆菌感染的当代药物治疗：一项叙述性综述
Infect Dis Ther. 2023 Feb;12(2):343-365. doi: 10.1007/s40121-022-00750-5. Epub 2023 Jan 7.
9
In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.非结核分枝杆菌对特地唑胺的体外敏感性
Infect Drug Resist. 2022 Aug 25;15:4845-4852. doi: 10.2147/IDR.S362583. eCollection 2022.
10
Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead.非结核分枝杆菌对抗生素和消毒剂的耐药性：挑战仍在前方。
Biomed Res Int. 2022 Feb 26;2022:8168750. doi: 10.1155/2022/8168750. eCollection 2022.
本文引用的文献
1
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.利奈唑胺治疗广泛耐药结核病：回顾性数据得到实验证据的证实。
Eur Respir J. 2013 Jul;42(1):288-90. doi: 10.1183/09031936.00191712.
2
In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates.三种抗结核药物联合方案对耐多药结核分枝杆菌分离株的体外作用。
Int J Antimicrob Agents. 2013 Mar;41(3):278-80. doi: 10.1016/j.ijantimicag.2012.11.011. Epub 2013 Jan 9.
3
Linezolid for treatment of chronic extensively drug-resistant tuberculosis.利奈唑胺治疗慢性广泛耐药结核病。
N Engl J Med. 2012 Oct 18;367(16):1508-18. doi: 10.1056/NEJMoa1201964.
4
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.利奈唑胺方案治疗耐多药结核病和广泛耐药结核病的疗效、安全性和耐受性：系统评价和荟萃分析。
Eur Respir J. 2012 Dec;40(6):1430-42. doi: 10.1183/09031936.00022912. Epub 2012 Apr 10.
5
Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.每日 300 毫克利奈唑胺治疗耐多药和广泛耐药结核病：51 例患者的更新分析。
J Antimicrob Chemother. 2012 Jun;67(6):1503-7. doi: 10.1093/jac/dks078. Epub 2012 Mar 8.
6
Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.利奈唑胺治疗耐药结核病的系统评价和荟萃分析。
Int J Tuberc Lung Dis. 2012 Apr;16(4):447-54. doi: 10.5588/ijtld.11.0451.
7
Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.美国医疗保险受益人群中非结核分枝杆菌肺病的流行率。
Am J Respir Crit Care Med. 2012 Apr 15;185(8):881-6. doi: 10.1164/rccm.201111-2016OC. Epub 2012 Feb 3.
8
Linezolid in the treatment of multidrug-resistant tuberculosis.利奈唑胺治疗耐多药结核病。
Clin Infect Dis. 2010 Jan 1;50(1):49-55. doi: 10.1086/648675.
9
Linezolid: a review of safety and tolerability.利奈唑胺：安全性与耐受性综述
J Infect. 2009 Sep;59 Suppl 1:S59-74. doi: 10.1016/S0163-4453(09)60009-8.
10
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.一项关于利奈唑胺治疗耐多药结核病安全性、耐受性及疗效的回顾性TBNET评估。
Eur Respir J. 2009 Aug;34(2):387-93. doi: 10.1183/09031936.00009509. Epub 2009 Mar 12.
Zotero 插件